New combo attack on rare abdominal cancer before surgery
NCT ID NCT03361436
Summary
This early-stage study is testing the safety and best dose of a chemotherapy drug called eribulin when given with radiation therapy before surgery. It involves 15 patients with a rare abdominal cancer called retroperitoneal liposarcoma. The goal is to see if this combined approach can shrink tumors more effectively to make surgery more successful and reduce the chance of the cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.